High and Mighty: Power Plus

#31 Dilip Shanghvi

62, Industrialist

Pharma king

Because, as managing director of Sun Pharmaceuticals, the world's fourth largest pharma company, he is driving a restructuring process post the acquisition of troubled Ranbaxy in March 2015 that will see pruning plants and staff, re-examining trade and incentive policies, and streamlining quality control processes.

Because, despite a Rs 46,800 crore erosion in his net worth after his company's stocks plunged on FDA warnings at his biggest factories and price slippage in the US market, he is the sixth richest in India and the country's richest in healthcare.

Because he has the prime minister's ear and on February 1 this year, was nominated director to the Central Board of the Reserve Bank of India until March 10, 2021.

Value creator

Started pharma trading firm with Rs 10,000 borrowed from his father in 1982. Sun Pharma had a market capitalisation of Rs 1.23 lakh crore